2nd Cardiac Safety Conference

Posted:
20
November 2007

2nd Cardiac Safety ConferenceBrief Description: ICH E14 QT Guidance were finalised (step 4) in May 2005. However, implementation of the new guidance (step 5) seems to have taken a different pace in different ICH regions, with US FDA leading the trend and Japan PMDA still developing their own version. The controversy regarding the predictive value of different non-clinical and clinical QT assays (including the TQT study itself) continue to underline the regional regulatory variations. As global experience is building up, Thorough QT (TQT) study designs are improving, sample size dropping and the use of positive control(s) becoming more sophisticated. The potential benefits of capturing and viewing multidimensional aspects of continuous QT and morphology data are gathering momentum with innovative technologies and methodologies coming up. Analysing and reporting QT data is also evolving while various TQT outcome scenarios are emerging. Concentration-effect modelling, promoted by US FDA, is increasingly taking a central role in the analysis and reporting of QT data. At the same time certain therapeutic classes, such as oncology and biological products, are still cast with uncertainty and face inconsistent regulatory requirements in the various regions.At the other end of the drug development spectrum, ongoing issues involving post marketing pharmacovigilance continue to make headlines. Cardiac Adverse Reactions, whether repolarisation-based, thrombosis-related or other are reported increasingly, involving a variety of drug classes. While legal and financial liabilities are still strong driving forces for cardiac safety pharmacovigilance, new public and regulatory initiatives are endorsing more proactive risk management and risk minimisation plans. These topics and others will be interactively discussed during the conference.Date: December 3 - 4, 2007Location: Dorint Praha Don Giovanni Hotel, Prague, Czech RepublicStand Number: 4

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more